Japanese database study tracks Real-World use of eye injection aflibercept 8 mg
NCT ID NCT06929143
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study examines how aflibercept 8 mg, an injection into the eye, is used in routine care for patients in Japan with age-related macular degeneration or diabetic macular edema. Researchers will analyze claims data from about 3000 patients to understand patient characteristics and treatment patterns over one year. No additional visits or tests are required.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept (Eylea) 8 mg injection into the eye
- What this could lead to
- If successful, this study will provide real-world data on how aflibercept 8 mg is used in Japanese patients, potentially guiding better treatment patterns for nAMD and DME.
- What could go wrong
- This is an observational study using existing data, so it cannot prove cause and effect. Results may be limited by data quality and may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bayer
Osaka, 5300001, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene therapy tame wet AMD for years?
- Laser zap before eye injection could cut needle count for wet AMD
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New eye injection shows promise for wet AMD in everyday practice